Posts Tagged: antibody

IP Protection for Antibody-based Assets in the Canadian Market and beyond

Together with Noel Courage, MI's Philip Goldbach co-authored an article published in BioTechnology Focus on IP rights and considerations surrounding antibody-based assets.  As the article states: Antibodies (immunoglobulins) and other antibody-derived biologics have become a mainstay of the biotechnology industry, both here in Canada and around the world. Novel antibodies are continuously being designed, modified, expressed and purified for a number of uses, including as therapeutics, diagnostics, or research tools. As is the case with other types of life science technologies, intellectual ... Read more

Triphase Accelerator announces new cancer collaboration with Sunnybrook Research Institute

TORONTO and SAN DIEGO (Feb. 26, 2015) — Triphase Accelerator Corporation has entered into an academic center collaboration with Sunnybrook Research Institute (SRI), the research arm of Sunnybrook Health Sciences Centre, a MaRS Innovation member institution. MaRS Innovation is also a Triphase investor. Under the agreement, SRI will assist in the development of Triphase’s novel, first-in-class, fully human bi-specific antibody TRPH 011 and evaluate the role of bifunctional targeting of VEGFR-2 and TIE 2 receptors in cancer. TRPH 011 binds and neutralizes VEGFR-2/KDR ... Read more

Triphase announces Celgene collaborations and license deal with PharmAbcine

Triphase Accelerator Corporation, a private, drug development company dedicated to advancing novel compounds through Phase II proof-of-concept, announced October 27, 2014 new and expanded strategic collaborations with Celgene Corporation. This announcement was covered in Genetic Engineering and Biotechnology News (GEN), BioCentury Extra (no link available), Pharmaceutical Business Review (no link available), Scrip and BioWorld Today (no link available). It builds on Triphase's original collaborative agreement with Celgene in January 2014. The company has also announced a new global license for a fully human, bi-specific ... Read more